Aripiprazole oral product + Placebo oral capsule
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pervasive Developmental Disorder
Conditions
Pervasive Developmental Disorder
Trial Timeline
Feb 1, 2009 → May 1, 2015
NCT ID
NCT00870727About Aripiprazole oral product + Placebo oral capsule
Aripiprazole oral product + Placebo oral capsule is a phase 3 stage product being developed by Bristol Myers Squibb for Pervasive Developmental Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00870727. Target conditions include Pervasive Developmental Disorder.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00870727 | Phase 3 | Completed |